PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Hyojin Kim, Jin-Haeng Chung
J Pathol Transl Med. 2019;53(4):199-206.   Published online 2019 May 2     DOI: https://doi.org/10.4132/jptm.2019.04.24
Citations to this article as recorded by Crossref logo
Do we need PD‐L1 as a biomarker for thyroid cytologic and histologic specimens?
Marc P. Pusztaszeri, Massimo Bongiovanni, Fadi Brimo
Cancer Cytopathology.2020; 128(3): 160.     CrossRef
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Andrea Botticelli, Pamela Vernocchi, Federico Marini, Andrea Quagliariello, Bruna Cerbelli, Sofia Reddel, Federica Del Chierico, Francesca Di Pietro, Raffaele Giusti, Alberta Tomassini, Ottavia Giampaoli, Alfredo Miccheli, Ilaria Grazia Zizzari, Marianna
Journal of Translational Medicine.2020;[Epub]     CrossRef
Immune checkpoint inhibitors in advanced non–small cell lung cancer: A metacentric experience from India
Santosh Kumar, Srujana Joga, Bivas Biswas, Deepak Dabkara, Kuruswamy Thurai Prasad, Navneet Singh, Prabhat Singh Malik, Sachin Khurana, Sandip Ganguly, Valliappan Muthu, Ullas Batra
Current Problems in Cancer.2020; : 100549.     CrossRef
Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
Jiyoung Yoon, Young Joo Suh, Kyunghwa Han, Hyoun Cho, Hye‐Jeong Lee, Jin Hur, Byoung Wook Choi
Thoracic Cancer.2020; 11(4): 993.     CrossRef
Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm
Lars H. Breimer, Petros Nousios, Louise Olsson, Hans Brunnström
Scandinavian Journal of Clinical and Laboratory Investigation.2020; : 1.     CrossRef
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Jean-David Fumet, Caroline Truntzer, Mark Yarchoan, Francois Ghiringhelli
European Journal of Cancer.2020; 131: 40.     CrossRef
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato
Cancers.2020; 12(5): 1125.     CrossRef
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Lee, Kim, Sung, Lee, Han, Kim, Choi
International Journal of Molecular Sciences.2019; 20(19): 4794.     CrossRef
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers
João Lobo, Ângelo Rodrigues, Rita Guimarães, Mariana Cantante, Paula Lopes, Joaquina Maurício, Jorge Oliveira, Carmen Jerónimo, Rui Henrique
Cancers.2019; 11(10): 1535.     CrossRef
Basis of PD1/PD-L1 Therapies
Barbara Seliger
Journal of Clinical Medicine.2019; 8(12): 2168.     CrossRef